Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair

Clinical Cancer Research

Volumn 15, Issue 20, 2009, Pages 6314-6320

  Bolderson, Emma ^a   Richard, Derek J ^a   Zhou, Bin Bing S ^b   Khanna, Kum Kum ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 7 HYDROXYSTAUROSPORINE; ADVEXIN; AG 014699; ANTINEOPLASTIC AGENT; ATM PROTEIN; AZD 2281; AZD 7762; BENZODIAZEPINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CAFFEINE; CAMPTOTHECIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; DEBROMOHYMENIALDISINE; DOUBLE STRANDED DNA; ETOPOSIDE; GEMCITABINE; GENDICINE; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PF 00477736; PROTEIN P53; QUINOLINOL DERIVATIVE; SCH 58500; TOPOTECAN; UNCLASSIFIED DRUG; XL 844;

BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ESOPHAGUS CANCER; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SMALL CELL CARCINOMA; SOLID TUMOR; STOMACH CANCER; THYROID CANCER; TOXICITY; TUMOR CELL; UTERINE TUBE CARCINOMA;

CELL CYCLE PROTEINS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DRUG DELIVERY SYSTEMS; GENES, CDC; GENOMIC INSTABILITY; HUMANS; MODELS, GENETIC; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 70350222210     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0096     Document Type: Review

References (73)

1. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-1753
2. Stewart GS, Maser RS, Stankovic T, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999;99:577-587 (Pubitemid 30004634)
3. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007;28:739-745 (Pubitemid 350217064)
4. Hakem R. DNA-damage repair; the good, the bad, and the ugly. EMBO J 2008;27:589-605. (Pubitemid 351273123)
5. Weterings E, Chen DJ. The endless tale of non-homologous end-joining. Cell Res 2008;18:114-124
6. van Gent DC, van der Burg M. Non-homologous end-joining, a sticky affair. Oncogene 2007;26:7731-7740
7. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-2196 (Pubitemid 32843830)
8. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
9. Richard DJ, Bolderson E, Cubeddu L, et al. Single-stranded DNA-binding protein hSSB1 is critical for genomic stability. Nature 2008;453:677-681 (Pubitemid 351769294)
10. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003;22:5612-5621 (Pubitemid 37279970)
11. Gatei M, Sloper K, Sorensen C, et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 2003;278:14806-14811 (Pubitemid 36799806)
12. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasiamutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A 2000;97:10389-10394 (Pubitemid 30707276)
13. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008;9:297-308.
14. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007;316:1160-1166 (Pubitemid 46877472)
15. Ahnesorg P, Smith P, Jackson SP. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 2006;124:301-313 (Pubitemid 43121979)
16. Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/ DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002;108:781-794
17. Helleday T. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res 2003;532:103-115
18. Pardo B, Gomez-Gonzalez B, Aguilera A. DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol Life Sci 2009;66:1039-1056
19. Sartori AA, Lukas C, Coates J, et al. Human CtIP promotes DNA end resection. Nature 2007;450:509-514 (Pubitemid 350190253)
20. Chen L, Nievera CJ, Lee AY, Wu X. Cell cycledependent complex formation of BRCA1.CtIP. MRN is important for DNA double-strand break repair. J Biol Chem 2008;283:7713-7720
21. Godthelp BC, Artwert F, Joenje H, Zdzienicka MZ. Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1. Oncogene 2002;21:5002-5005 (Pubitemid 34888346)
22. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999;59:3547-3551 (Pubitemid 29381849)
23. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007;6:923-935 (Pubitemid 46880473)
24. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-4382
25. Sabisz M, Skladanowski A. Modulation of cellular response to anticancer treatment by caffeine: inhibition of cell cycle checkpoints, DNA repair and more. Curr Pharm Biotechnol 2008;9:325-336
26. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9159 (Pubitemid 39665530)
27. Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiec©\ tasia mutated. J Clin Invest 2007;117:1440-1449 (Pubitemid 46718432)
28. Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN- 01. J Biol Chem 2000;275:5600-5605 (Pubitemid 30115197)
29. Welch S, Hirte HW, Carey MS, et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 2007;106:305-310 (Pubitemid 47096653)
30. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007;13:1955-1960 (Pubitemid 46649860)
31. Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs 2008;17:1331-1340
32. Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-2966
33. Matthews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007;6:104-110 (Pubitemid 46173886)
34. Blasina A, Hallin J, Chen E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008;7:2394-2404
35. Bao S,Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760
36. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
37. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7:979-987
38. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604. (Pubitemid 37328926)
39. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004;2:E36.
40. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005;5:3-8. (Pubitemid 40321795)
41. Girard PM, Foray N, Stumm M, et al. Radiosensitivity in Nijmegen Breakage Syndrome cells is attributable to a repair defect and not cell cycle checkpoint defects. Cancer Res 2000;60:4881-4888 (Pubitemid 30701504)
42. Cariveau MJ, Tang X, Cui XL, Xu B. Characterization of an NBS1 C-terminal peptide that can inhibit ataxia telangiectasia mutated (ATM)- mediated DNA damage responses and enhance radiosensitivity. Mol Pharmacol 2007;72:320-326 (Pubitemid 47124112)
43. Dupre A, Boyer-Chatenet L, Sattler RM, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-50-Nbs1 complex. Nat Chem Biol 2008;4:119-125
44. Christodoulopoulos G, Malapetsa A, Schipper H, Golub E, Radding C, Panasci LC. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin Cancer Res 1999;5:2178-2184 (Pubitemid 29399275)
45. Henning W, Sturzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 2003;193:91-109. (Pubitemid 37340146)
46. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun 1998;245:319-324
47. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP. Ribozyme minigenemediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001;29:1534-1538 (Pubitemid 32288501)
48. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005;7:1044-1052 (Pubitemid 41195066)
49. Richard DJ, Bolderson E, Khanna KK. Multiple human single-stranded DNA binding proteins function in genome maintenance: structural, biochemical and functional analysis. Crit Rev Biochem Mol Biol 2009:1-19, Epub 2009 Apr 14.
50. Andrews BJ, Turchi JJ. Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair. Mol Cancer Ther 2004;3:385-391
51. Lees-Miller SP, Godbout R, Chan DW, et al. Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 1995;267:1183-1185
52. Ouyang H, Nussenzweig A, Kurimasa A, et al. Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med 1997;186:921-929 (Pubitemid 27407353)
53. Deriano L, Guipaud O, Merle-Beral H, et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 2005;105:4776-4783 (Pubitemid 40807303)
54. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 1997;3:1149-1156
55. Shinohara ET, Geng L, Tan J, et al. DNAdependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 2005;65:4987-4992 (Pubitemid 40827302)
56. Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66:5354-5362 (Pubitemid 43844961)
57. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008;18:80-86 (Pubitemid 351694447)
58. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-917 (Pubitemid 40559005)
59. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921 (Pubitemid 40559006)
60. Hay T, Matthews JR, Pietzka L, et al. Poly (ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009;69:3850-3855
61. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134
62. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCAdeficient advanced breast cancer. J Clin Oncol 2009;27:CRA501.
63. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009;27:5500.
64. Ashwell S, Zabludoff S. DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008;14:4032-4037
65. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004;2:1-8.
66. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848
67. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55:96-107.
68. Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006;6:55-61.
69. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005;16:1016-1027 (Pubitemid 41324561)
70. Harris N, Brill E, Shohat O, et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 1986;6:4650-4656 (Pubitemid 17217402)
71. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-963 (Pubitemid 17004567)
72. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602. (Pubitemid 39535748)
73. BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium. Cancer Biol Ther 2009;8:2-3.